BUSINESS
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
CNBC BusinessMonday, November 16, 2026 at 3:00 PM
RedScroll Brief
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
RedScroll Signal
- Impact
- High
- Category
- Business
- Market relevance
- High
- Why it matters
- Corporate and market moves reprice risk and reveal where power and cash are concentrating. Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12. Investors will watch earnings, rates, and competitive positioning connected to Novo and Wegovy.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating.
Background
CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
CNBC Business published: Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Investors will watch earnings, rates, and competitive positioning connected to Novo and Wegovy.
More on
Related stories
- Trump Says Huang Should Return to Nvidia After ‘Big Apology’
Bloomberg MarketsBUSINESS
- Gap names new Athleta CEO, says Old Navy turnaround is seeing signs of progress
CNBC BusinessBUSINESS
- Gap names new Athleta CEO, lowers full-year guidance
CNBC BusinessBUSINESS
- Anthropic soars, but it may soon be back, cap in hand
The Economist BusinessBUSINESS
- Bartleby newsletter: Why you weren’t invited to that meeting
The Economist BusinessBUSINESS
- Anthropic’s giant IPO puts the heat on OpenAI
The Economist BusinessBUSINESS
Source
CNBC Business
Original reporting by CNBC Business. RedScroll provides an extractive briefing only.